Literature DB >> 16525661

Disordered expression of HOX genes in human non-small cell lung cancer.

Motoki Abe1, Jun-Ichi Hamada, Osamu Takahashi, Yoko Takahashi, Mitsuhiro Tada, Masaki Miyamoto, Toshiaki Morikawa, Satoshi Kondo, Tetsuya Moriuchi.   

Abstract

We hypothesized that the disordered tissue architecture in cancer results from the cells executing the program designed during ontogeny in a spatio-temporally inappropriate manner. HOX genes are known as master regulators of embryonic morphogenesis, and encode transcription factors which regulate the transcription of the downstream genes to realize the program of body plan. In this study, we quantified the expression levels of 39 HOX genes in 41 human non-small cell lung cancer (non-SCLC) and non-cancerous lung tissues by a comprehensive analysis system based on the real-time RT-PCR method. We found that the expression levels of HOXA1, A5, A10 and C6 in squamous cell carcinoma tissues (and HOXA5 and A10 in adenocarcinoma tissues) were significantly higher than those in the non-cancerous tissues. Comparison of HOX gene expressions between adenocarcinoma and squamous cell carcinoma tissues showed higher expressions of HOXA1, D9, D10 and D11 in squamous cell carcinoma tissues than in adenocarcinoma tissues. Immunohistochemical analysis revealed that HOXA5 and A10 proteins were localized in the cytoplasm of tumor cells in both adenocarcinoma and squamous cell carcinoma tissues. These results suggest that the disordered patterns of HOX gene expressions were involved not only in the development of non-SCLC but also in the histologically aberrant diversity such as adenocarcinoma and squamous cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16525661

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  43 in total

1.  Silencing HoxA1 by intraductal injection of siRNA lipidoid nanoparticles prevents mammary tumor progression in mice.

Authors:  Amy Brock; Silva Krause; Hu Li; Marek Kowalski; Michael S Goldberg; James J Collins; Donald E Ingber
Journal:  Sci Transl Med       Date:  2014-01-01       Impact factor: 17.956

Review 2.  The Hox genes and their roles in oncogenesis.

Authors:  Nilay Shah; Saraswati Sukumar
Journal:  Nat Rev Cancer       Date:  2010-04-01       Impact factor: 60.716

3.  A functional in vivo screen for regulators of tumor progression identifies HOXB2 as a regulator of tumor growth in breast cancer.

Authors:  Pamela J Boimel; Cristian Cruz; Jeffrey E Segall
Journal:  Genomics       Date:  2011-06-13       Impact factor: 5.736

4.  MicroRNA miR-196a is a central regulator of HOX-B7 and BMP4 expression in malignant melanoma.

Authors:  Simone Braig; Daniel W Mueller; Tanja Rothhammer; Anja-Katrin Bosserhoff
Journal:  Cell Mol Life Sci       Date:  2010-05-18       Impact factor: 9.261

5.  Abnormal gene expression and gene fusion in lung adenocarcinoma with high-throughput RNA sequencing.

Authors:  Z-H Yang; R Zheng; Y Gao; Q Zhang; H Zhang
Journal:  Cancer Gene Ther       Date:  2014-02-07       Impact factor: 5.987

6.  Targeting HOX and PBX transcription factors in ovarian cancer.

Authors:  Richard Morgan; Lynn Plowright; Kevin J Harrington; Agnieszka Michael; Hardev S Pandha
Journal:  BMC Cancer       Date:  2010-03-10       Impact factor: 4.430

Review 7.  HOX genes and their role in the development of human cancers.

Authors:  Seema Bhatlekar; Jeremy Z Fields; Bruce M Boman
Journal:  J Mol Med (Berl)       Date:  2014-07-05       Impact factor: 4.599

8.  miEAA: microRNA enrichment analysis and annotation.

Authors:  Christina Backes; Qurratulain T Khaleeq; Eckart Meese; Andreas Keller
Journal:  Nucleic Acids Res       Date:  2016-04-29       Impact factor: 16.971

9.  ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells.

Authors:  Jan S Moreb; Henry V Baker; Lung-Ji Chang; Maria Amaya; M Cecilia Lopez; Blanca Ostmark; Wayne Chou
Journal:  Mol Cancer       Date:  2008-11-24       Impact factor: 27.401

10.  HOX transcription factors are potential therapeutic targets in non-small-cell lung cancer (targeting HOX genes in lung cancer).

Authors:  L Plowright; K J Harrington; H S Pandha; R Morgan
Journal:  Br J Cancer       Date:  2009-01-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.